The Motley Fool

Why I’d ditch this defensive dividend stock to buy AstraZeneca plc

Dairy Crest (LSE: DCG) today reported a “strong first half of the year” in a pre-close trading update for the six months to 30 September. Management said it expects combined volumes of its four key brands — Cathedral City, Clover, Country Life and Frylight — to be ahead of the same period last year, with group profit also ahead. It added: “Our profit expectations for the full year are unchanged.”

The shares are trading up 1.6% at 616p, as I’m writing, putting the FTSE 250 firm on a forward price-to-earnings (P/E) ratio of 16.4, with a prospective dividend yield of 3.7%. This valuation looks quite attractive for a company in the defensive food producers sector but I see greater attraction in a similarly rated stock in another defensive sector.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

At a share price of 4,700p, AstraZeneca (LSE: AZN) trades on a forward P/E of 16.8, with a prospective dividend yield of 4.4%. If I needed to free-up funds to invest in the FTSE 100 pharma giant, I’d be willing to sacrifice Dairy Crest.

Revenues and profits

AstraZeneca’s revenue has fallen from $28bn to $23bn over the last five years, as patent expiries on some of its top-selling products have taken a toll. Meanwhile, Dairy Crest’s revenue has declined more modestly from £430m to £417m (after stripping out its Dairies operation, which it sold in 2015).

Top-line growth is essential for profit growth in the long run and the good news is that Dairy Crest’s revenue is forecast to begin increasing from this year and AstraZeneca’s from next year. Even if the pharma group falls short of chief executive Pascal Soriot’s ambitious target of $45bn in annual revenues by 2023 — as its strong pipeline of new drugs begins to bear fruit — I expect it to comfortably outpace the top-line growth of Dairy Crest.

The vast majority of Dairy Crest’s revenues come from the mature UK market but it’s diversification into supplying ingredients for infant formula — a high-growth, high-margin global market — should help profits move higher. Nevertheless, I reckon AstraZeneca’s cost-base restructuring of the last few years should lead to superior profit advances as its top-line growth kicks in.

Dividends and debt

Dairy Crest has increased its dividend — if rather unspectacularly — from 20.7p to 22.5p over the last five years. However, its net debt has increased from £60m to £249m during the period, giving sky-high gearing of 346%. Furthermore, despite its defensive qualities, it rebased its dividend 25% lower back in 2009.

By contrast, AstraZeneca has managed to maintain its dividend at 280 cents over the past five years of protracted pressure on revenues and profits. Its net debt has also risen (from $1.4bn to $10.7bn) but gearing is a far more comfortable 72%.

If my top- and bottom-line growth expectations for AstraZeneca are on the mark, it should be capable of providing a superior dividend return in due course, particularly from a current starting yield of 4.4% versus Dairy Crest’s 3.7%

Other qualities

Finally, Dairy Crest not only has far more limited geographical diversification than AstraZeneca, but also higher customer-concentration risk. Almost half its revenue comes from just three customers.

This contrasts with its larger and more diversified food producer peer Unilever, which has no single customer accounting for 10% or more of its revenue. And like Unilever, AstraZeneca has a wide diversity of customers and suppliers across different geographic areas. Only one wholesaler accounts for greater than 10% of its product sales.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.